Q3 2025 Cigna Group Earnings Call Transcript
Key Points
- The Cigna Group (CI) reported strong third-quarter 2025 results with revenues of $69.7 billion and adjusted earnings of $7.83 per share.
- The company is introducing a new rebate-free model for pharmacy benefits, aimed at improving healthcare affordability and consumer experience.
- Evernorth Health Services delivered 11% adjusted earnings growth in its Specialty and Care Services businesses, reflecting strong specialty volume growth and increased biosimilar adoption.
- The Cigna Group (CI) has secured long-term renewals and extensions with major clients, including the US Department of Defense, Prime Therapeutics, and Centene, ensuring stability through the end of the decade.
- The company is investing in Shields Health Solutions to expand its specialty capabilities, targeting the $400 billion specialty market.
- The Pharmacy Benefit Services segment is expected to face margin pressure over the next two years due to investments in the new rebate-free model and modified margin profiles from large client renewals.
- The individual exchange business has impacted the medical care ratio, leading to a higher expected MCR for the full year 2025.
- The absence of nonrecurring benefits from divested Medicare businesses and individual exchange business adjustments will be a headwind for 2026.
- The transition to the new pharmacy benefits model will incur significant short-term investment and transition costs, impacting 2026 and 2027 financials.
- The company expects Evernorth's operating income to decline slightly in 2026, driven by the Pharmacy Benefit Services segment.
Ladies and gentlemen, thank you for standing by for The Cigna Group's third-quarter 2025 results review. (Operator Instructions) As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded.
We'll begin by turning the conference over to Ralph Giacobbe. Please go ahead.
Great. Thanks. Good morning, everyone. Thank you for joining today's call. I'm Ralph Giacobbe, Senior Vice President of Investor Relations. With me on the line this morning are David Cordani, The Cigna Group's Chairman and Chief Executive Officer; Brian Evanko, President and Chief Operating Officer; and Ann Dennison, Chief Financial Officer.
In our remarks today, David, Brian and Ann will cover a number of topics, including our third quarter 2025 financial results and our financial outlook for 2025. Following their prepared remarks, David, Brian and Ann will be available for Q&A.
As noted in our earnings release, when describing our financial results, we use certain
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
